Recent advances in the contribution of noncoding RNAs to cisplatin resistance in cervical cancer.

Xin Wen,Manhua Cui,Shui Liu,Jiyao Sheng

doi:10.7717/peerj.9234

Abstract

Cervical cancer (CC) remains a major disease burden on the female population worldwide. Chemotherapy with cisplatin (cis-diamminedichloroplatinum (II); CDDP) and related drugs are the main treatment option for CC; however, their efficacy is limited by the development of drug resistance. Noncoding RNAs (ncRNAs) have been found to play critical roles in numerous physiological and pathological cellular processes, including drug resistance of cancer cells. In this review, we describe some of the ncRNAs, including miRNAs, lncRNAs and circRNAs, that are involved in the sensitivity/resistance of CC to CDDP-based chemotherapy and discuss their mechanisms of action. We also describe some ncRNAs that could be therapeutic targets to improve the sensitivity of CC to CDDP-based chemotherapy.

Highlights

There are 569,847 new cervical cancer (CC) diagnoses and 311,365 deaths from CC annually worldwide (Bray et al, 2018)
Chemotherapy for CC is mainly used in three aspects: (1) neoadjuvant chemotherapy (NACT) to shrink the tumor before operation; (2) concurrent chemoradiotherapy (CCRT) for middle and advanced patients; (3) palliative chemotherapy for patients with recurrence or metastasis (Moore, 2008; Moore et al, 2010; Pfaendler & Tewari, 2016)
We focus on studies examining the mechanisms of action of ncRNAs and the potential applications of ncRNAs in predicting CDDP sensitivity and improving chemotherapy regimens in CC, which might provide new therapeutic strategies for patients with CDDP-resistant CC

Summary

INTRODUCTION

There are 569,847 new cervical cancer (CC) diagnoses and 311,365 deaths from CC annually worldwide (Bray et al, 2018). Recent advances in the contribution of noncoding RNAs to cisplatin resistance in cervical cancer. Deregulation of ncRNAs can affect the outcome of cancer treatment and allow tumors to acquire drug-resistant phenotypes (Corrà et al, 2018; Wang et al, 2019). An increasing number of studies has shown that ncRNAs play an essential role in CC (Chaichian et al, 2020; He et al, 2016; Hosseini et al, 2017; Sharma, Dua & Agarwal, 2014), and several classes of ncRNAs, such as miRNAs, lncRNAs and circRNAs, have been associated with CDDP resistance, making them important potential therapeutic targets (Matsui & Corey, 2017). We focus on studies examining the mechanisms of action of ncRNAs and the potential applications of ncRNAs in predicting CDDP sensitivity and improving chemotherapy regimens in CC, which might provide new therapeutic strategies for patients with CDDP-resistant CC

SURVEY METHODOLOGY

CONCLUSIONS